Current problems in cancer. Case reports最新文献_第5页

Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report 使用 pembrolizumab 治疗晚期子宫内膜癌，未进行手术干预或全身化疗，却完成了持久应答：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-17 DOI: 10.1016/j.cpccr.2024.100285

Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda

{"title":"Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report","authors":"Anusha Adkoli , Rodrigo Alcorta Proaño , Eugenia Girda","doi":"10.1016/j.cpccr.2024.100285","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100285","url":null,"abstract":"<div><p>Endometrial cancer remains the most common gynecologic malignancy in the United States. Novel molecular targets are being explored for treatment of advanced uterine. Molecular targets in signaling cascades have been identified including immune checkpoint inhibitors. This is a case of 63-year-old G0 with locally advanced unstaged undifferentiated/dedifferentiated TMB-H/MSI endometrial cancer, who had progression of disease after neoadjuvant radiation therapy. She was intolerant of systemic chemotherapy and declined surgical intervention but had subsequent complete response after 9 cycles of pembrolizumab. She has remained disease free for a total of 30 months (about 2.5 years) of follow up. Standard of care for advanced uterine cancer includes multimodality treatment with surgery, radiation, and systemic chemotherapy. This patient's response to treatment demonstrates that immunotherapy as an upfront treatment may be a reasonable alternative for patients with endometrial cancer with specific molecular profile regardless of histology.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000085/pdfft?md5=928435e2c6ff4093a59dd325e40539ab&pid=1-s2.0-S2666621924000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Merkel cell carcinoma of the breast: A case report 乳腺梅克尔细胞癌：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-16 DOI: 10.1016/j.cpccr.2024.100287

Catherine McNulty , Shabnam Mortazavi , Joseph Giessinger , Sepehr Hamidi

引用次数: 0

Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report 通过FoundationOne检测发现表皮生长因子受体基因第20外显子H773L/V774M的共突变，并接受奥希替尼治疗：病例报告

Current problems in cancer. Case reports Pub Date : 2024-03-08 DOI: 10.1016/j.cpccr.2024.100286

Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai

{"title":"Detection of a co-mutation in the epidermal growth factor receptor gene exon 20 H773L/V774M by FoundationOne test and treatment with osimertinib: A case report","authors":"Hiroshi Yoshida , Hiroaki Ozasa , Kentaro Hashimoto , Yusuke Shima , Keiichiro Suminaga , Hitomi Ajimizu , Takashi Nomizo , Hironori Yoshida , Masahiro Yoshioka , Masashi Kanai , Takehito Shukuya , Manabu Muto , Toyohiro Hirai","doi":"10.1016/j.cpccr.2024.100286","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100286","url":null,"abstract":"<div><p>Among cases of non-small cell lung cancer (NSCLC) with EGFR mutations, NSCLC with deletions in EGFR exon 19 or 21 L858R account for 85 %. Frequency of NSCLC with minor mutations in EGFR is about 9 %, whilst EGFR exon 20 insertion mutation account for 6 % of the cases, determining it as a rare mutation. In this case, minor EGFR mutation and compound mutation EGFR H773L/V774M, were detected. Oncomine Dx target test (Oncomine), FoundationOne, and Amoy Dx polymerase chain reaction panel (Amoy 9-in-1 kit) were used as companion diagnostic tests. FoundationOne was the only one able to detect EGFR exon 20 H773L/V774M mutations. Drug therapy for NSCLC with compound mutations in EGFR exon 20 is not yet established. Unsuccessful treatments with EGFR-TKIs such as Erlotinib, Gefitinib, and Afatinib have been reported. There have also been reports of successful treatments with Osimertinib in combination with Bevacizumab. In the presented case, Osimertinib monotherapy was successful in treating NSCLC with EGFR exon 20 compound mutation. Osimertinib, therefore, has the potential to treat NSCLC with EGFR exon 20 H773L/V774M mutation, and can be a key drug for treating EGFR rare mutations.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000097/pdfft?md5=747e780082018d7614de042efcf5d883&pid=1-s2.0-S2666621924000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma cfDNA in Carcinoma of unknown primary: A case series 血浆 cfDNA 在不明原发癌中的应用：一个病例系列

Current problems in cancer. Case reports Pub Date : 2024-02-10 DOI: 10.1016/j.cpccr.2024.100283

Rajat Thawani , Ajay Mohinani , Mason McLellan , Nima Nabavizadeh , Sean Goodyear , Adel Kardosh

引用次数: 0

Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report 与免疫检查点抑制剂治疗转移性结直肠癌相关的蓝墨水纹身反应，一份病例报告

Current problems in cancer. Case reports Pub Date : 2024-02-04 DOI: 10.1016/j.cpccr.2024.100281

Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney

{"title":"Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report","authors":"Nolan Holley , Jessica Patterson , Michael Kolodney , Joanna Kolodney","doi":"10.1016/j.cpccr.2024.100281","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100281","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) have revolutionized the field of oncology and transformed the management of many malignancies, especially for patients with metastatic disease. Dermatologic toxicities are among the most common immune-related adverse events (irAEs) of ICIs and can manifest in various ways. We report the case of a 56-year-old male with metastatic colorectal cancer treated with ipilimumab and nivolumab who then developed dermatologic abnormalities confined to the blue-ink regions of his long-standing multicolored tattoos on multiple areas of his body. The patient's reaction resolved after intralesional injection of triamcinolone acetonide. Tattoo reactions associated with ICI treatment are rare, and to our knowledge, there have been no published cases of dermatologic irAEs isolated to blue-pigmented areas of multicolored tattoos. It is of great importance to have awareness of the possibility of this type of reaction and to provide appropriate care for patients undergoing treatment with ICIs.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000048/pdfft?md5=d5613591666210d0658f522c5ce12bbc&pid=1-s2.0-S2666621924000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139719195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion for methotrexate-induced acute kidney injury in an elderly lymphoma patient 一名老年淋巴瘤患者因甲氨蝶呤诱发急性肾损伤，在接受血液透析和炭化血液灌流治疗后连续接受短期皮质类固醇治疗

Current problems in cancer. Case reports Pub Date : 2024-02-03 DOI: 10.1016/j.cpccr.2024.100282

Misato Tane , Hiroki Hosoi , Hideki Kosako , Yukiko Yamano , Takayuki Hiroi , Shogo Murata , Toshiki Mushino , Shin-Ichi Araki , Takashi Sonoki

{"title":"Short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion for methotrexate-induced acute kidney injury in an elderly lymphoma patient","authors":"Misato Tane , Hiroki Hosoi , Hideki Kosako , Yukiko Yamano , Takayuki Hiroi , Shogo Murata , Toshiki Mushino , Shin-Ichi Araki , Takashi Sonoki","doi":"10.1016/j.cpccr.2024.100282","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100282","url":null,"abstract":"<div><p>Acute kidney injury (AKI) due to delayed methotrexate (MTX) elimination is a severe potential adverse event of high-dose (HD)-MTX treatment. However, no treatment for HD-MTX-induced AKI has been established. In addition, there are no reports of corticosteroids being administered for HD-MTX-induced AKI. Here, we report the case of a 77-year-old male with central nervous system lymphoma, who developed an AKI after the second course of HD-MTX. He underwent charcoal hemoperfusion and hemodialysis immediately after the development of the AKI. He also received short-term corticosteroid therapy due to inflammatory findings and a positive drug-induced lymphocyte stimulation test for MTX. Our case suggests that short-term corticosteroid therapy consecutive to hemodialysis and charcoal hemoperfusion may be useful for AKI induced by delayed MTX elimination even in the elderly.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266662192400005X/pdfft?md5=080e6d8d893f78355246fce604eb8a27&pid=1-s2.0-S266662192400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139714561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms 一例具有组织学转化和多重耐药机制的表皮生长因子受体突变肺癌 IV 期疑难病例

Current problems in cancer. Case reports Pub Date : 2024-02-02 DOI: 10.1016/j.cpccr.2024.100284

Joel Rivera-Concepcion , Ying-Chun Lo , Dipesh Uprety , Alex A. Adjei , Vinicius Ernani , Konstantinos Leventakos

引用次数: 0

Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series 胃肠道间质瘤 (GIST) 患者因伊马替尼诱发肺炎而陷入治疗困境：病例系列

Current problems in cancer. Case reports Pub Date : 2024-01-30 DOI: 10.1016/j.cpccr.2024.100280

Deborah van de Wal , Evelyne Roets , Roos F. Bleckman , Jorn Nützinger , Birthe C. Heeres , J. Martijn Kerst , Mahmoud Mohammadi , Anna K.L. Reyners , Ingrid M.E. Desar , Astrid W. Oosten , Neeltje Steeghs , Winette T.A. van der Graaf

{"title":"Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series","authors":"Deborah van de Wal , Evelyne Roets , Roos F. Bleckman , Jorn Nützinger , Birthe C. Heeres , J. Martijn Kerst , Mahmoud Mohammadi , Anna K.L. Reyners , Ingrid M.E. Desar , Astrid W. Oosten , Neeltje Steeghs , Winette T.A. van der Graaf","doi":"10.1016/j.cpccr.2024.100280","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100280","url":null,"abstract":"<div><h3>Introduction</h3><p>Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease.</p></div><div><h3>Methods</h3><p>Patients registered within the Dutch GIST Registry (DGR) were reviewed. For the patients identified with an imatinib-induced pneumonitis we reported the time on imatinib to develop pneumonitis, how the pneumonitis was diagnosed, graded and managed, and how the GIST treatment was managed.</p></div><div><h3>Cases</h3><p>Of the 1934 patients registered in the DGR, 1161 patients received imatinib at some point, of which nine patients (0.8 %) were identified with an imatinib-induced pneumonitis. At time of the pneumonitis, patients received a daily imatinib dose of 200–400 mg for a mean duration of 486 days. One patient was able to continue imatinib in a lower dose, in the other eight patients imatinib was interrupted, and six of these patients started prednisolone treatment. After management of the imatinib-induced pneumonitis, four patients stopped imatinib permanently, two patients were rechallenged with imatinib, and two patients started treatment with second-line sunitinib.</p></div><div><h3>Conclusion</h3><p>Imatinib-induced pneumonitis is a rare side effect, which may affect GIST management considerably. After the management of imatinib-induced pneumonitis, clinicians are left with difficult treatment dilemmas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000036/pdfft?md5=30301d16ab28aaf6cd3f1b1875384bd4&pid=1-s2.0-S2666621924000036-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139714562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic renal angiosarcoma to the liver with underlying JAK2 mutation 转移至肝脏的肾血管肉瘤伴有潜在的 JAK2 基因突变

Current problems in cancer. Case reports Pub Date : 2024-01-29 DOI: 10.1016/j.cpccr.2024.100279

Ankita Kapoor , Bei Yang , Parikshit Padhi

引用次数: 0

ML: Early Breast Cancer Diagnosis ML：早期乳腺癌诊断

Current problems in cancer. Case reports Pub Date : 2024-01-09 DOI: 10.1016/j.cpccr.2024.100278

Seyed Matin Malakouti, Mohammad Bagher Menhaj, Amir Abolfazl Suratgar

{"title":"ML: Early Breast Cancer Diagnosis","authors":"Seyed Matin Malakouti, Mohammad Bagher Menhaj, Amir Abolfazl Suratgar","doi":"10.1016/j.cpccr.2024.100278","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100278","url":null,"abstract":"<div><p>Breast cancer is the most common malignancy among women worldwide, often characterized by the uncontrolled proliferation of breast cells, leading to the formation of lumps or tumors that can be detected through medical imaging such as X-rays. Distinguishing between benign and malignant tumors presents a significant challenge in the diagnosis of breast cancer.</p><p>In this study, machine learning methods, including Logistic Regression, Gradient Boosting, Ada Boost, Random Forest, and Gaussian NB with Grid Search, were employed to differentiate between healthy individuals and those with malignancies. The results revealed that the Random Forest algorithm exhibited the highest performance in predicting breast cancer, accurately identifying 99 % of both healthy and affected individuals. Additionally, both Gradient Boosting and Ada Boost demonstrated a similar level of accuracy, correctly distinguishing 98 % of healthy and affected individuals.</p><p>Conversely, Gaussian NB performed the least effectively, with an accuracy of 91 % in differentiating between healthy and affected individuals, highlighting its comparatively lower predictive capability for breast cancer.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000012/pdfft?md5=ceb405394533ced110a3290c7dbc4ff6&pid=1-s2.0-S2666621924000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139436532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0